Research Topics
Genomes and Genes | Sean I SavitzSummaryAffiliation: Baylor College of Medicine Country: USA Publications
| Collaborators
|
Detail Information
Publications
Shift analysis versus dichotomization of the modified Rankin scale outcome scores in the NINDS and ECASS-II trialsSean I Savitz
Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Stroke 38:3205-12. 2007..The SAINT I trial that showed a significant benefit of the neuroprotectant NXY-059 used a novel outcome for acute ischemic stroke trials: a shift toward good functional outcome on the 7-category modified Rankin scale (mRS)...- Pooled analysis of patients with thunderclap headache evaluated by CT and LP: is angiography necessary in patients with negative evaluations?Sean I Savitz
Department of Neurology, University of Texas Houston Medical School, Houston, TX 77030, USA
J Neurol Sci 276:123-5. 2009..Some have suggested that angiography is also indicated in this common clinical situation. Is evaluation with brain CT and LP for thunderclap headache to rule out SAH sufficient and is angiography needed?.. - Outcome analysis in clinical trial design for acute stroke: physicians' attitudes and choicesSean I Savitz
Department of Neurology, University of Texas Houston Medical School, Houston, TX 77030, USA
Cerebrovasc Dis 26:156-62. 2008..Recent studies have introduced more sensitive outcome measures such as the shift analysis to detect a treatment effect in AIS trials and are also including imaging as a surrogate of injury... - Thunderclap headache with normal CT and lumbar puncture: further investigations are unnecessary: forSean I Savitz
University of Texas Houston Medical School, Department of Neurology, 6431 Fannin Street, Houston, TX 77030, USA
Stroke 39:1392-3. 2008 - A Critique of SAINT II: wishful thinking, dashed hopes, and the future of neuroprotection for acute strokeSean I Savitz
Department of Neurology, University of Texas, Houston Medical School, Houston, Texas, USA
Stroke 39:1389-91. 2008 - Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) IISean I Savitz
Department of Neurology, University of Texas Medical School at Houston, Houston, TX 77030, USA
Stroke 42:825-9. 2011.... - Functional assessments in the rodent stroke modelKrystal L Schaar
University of Texas Medical School at Houston, Department of Neurology, 6431 Fannin Houston, TX 77030, USA
Exp Transl Stroke Med 2:13. 2010..While there is no perfect test, there are many assessments that are sensitive to detecting the array of impairments, from global to modality specific, after stroke... - Increased blood-brain barrier permeability on perfusion CT might predict malignant middle cerebral artery infarctionHesna Bektas
Department of Neurology, The University of Texas Houston Medical School, Houston, TX 77030, USA
Stroke 41:2539-44. 2010..The purpose of this study was to determine the predictive value of blood-brain barrier permeability measured using perfusion CT for development of malignant middle cerebral artery infarction requiring hemicraniectomy (HC)... - Identifying patients at high risk for poor outcome after intra-arterial therapy for acute ischemic strokeHen Hallevi
Department of Neurology, University of Texas Health Science Center at Houston, Houston, TX 77030, USA
Stroke 40:1780-5. 2009..Despite high rates of recanalization, the outcome is variable. We attempted to identify predictors of outcome that will enable better patient selection for IAT... - Stem cells and stroke: are we further away than anyone is willing to admit?Sean I Savitz
Department of Neurology, University of Texas Medical School at Houston, 6431 Fannin Street, Houston, TX 77030, USA
Int J Stroke 7:34-5. 2012..We are at least 5-10 years away from knowing if cell therapies will improve clinical outcome in stroke patients. The use of stem cells in stroke therapy remains investigational only... - Intravenous autologous bone marrow mononuclear cells for ischemic strokeSean I Savitz
Department of Neurology, University of Texas Medical School at Houston, Houston, TX, USA
Ann Neurol 70:59-69. 2011..Mononuclear cells (MNCs) from the bone marrow reduce neurological deficits in animal stroke models. We determined if autologous MNC infusion was feasible and safe in patients with ischemic stroke... - Thrombolytic therapy for patients who wake-up with strokeAndrew D Barreto
Stroke Division, Department of Neurology, University of Texas Houston Medical School, Houston, USA
Stroke 40:827-32. 2009..The purpose of this study was to describe our center's experience with off-label, compassionate thrombolysis for wake-up stroke (WUS) patients... - Recovery after ischemic stroke: criteria for good outcome by level of disability at day 7Hen Hallevi
Department of Neurology, Vascular Neurology Program, University of Texas at Houston Health Science Center, Houston, Texas 77030, USA
Cerebrovasc Dis 28:341-8. 2009..Ischemic stroke is a leading cause of morbidity. Assessing the chances of recovery is critical to optimize poststroke care... - Does study enrollment delay treatment with intravenous thrombolytics for acute ischemic stroke?Sheryl Martin-Schild
Department of Neurology, University of Texas Medical SchoolHouston Medical School, Houston, Texas 77030, USA
Stroke 40:663. 2009..Enrollment in acute stroke trials at a stroke center with multiple study protocols may delay the initiation of intravenous thrombolytics in patients who present within 3 hours of symptom onset... - Thrombus burden is associated with clinical outcome after intra-arterial therapy for acute ischemic strokeAndrew D Barreto
Department of Neurology, Stroke Division, University of Texas, Houston Health Science Center, Houston, TX 77030, USA
Stroke 39:3231-5. 2008..The aim of the study was to determine the impact of intra-arterial thrombus burden on intra-arterial treatment (IAT) and clinical outcome... - Necroptosis, a novel form of caspase-independent cell death, contributes to neuronal damage in a retinal ischemia-reperfusion injury modelDaniel M Rosenbaum
Department of Neurology, SUNY Downstate Medical Center, Brooklyn, New York, USA
J Neurosci Res 88:1569-76. 2010..Conclusion: Necroptosis is an important mode of neuronal cell death and involves autophagy in a model of retinal ischemia... - Therapeutic time window and dose response of autologous bone marrow mononuclear cells for ischemic strokeBing Yang
Department of Neurology, University of Texas Medical School at Houston, Houston, TX 77030, USA
J Neurosci Res 89:833-9. 2011..In conclusion, we found a maximum reduction in neurological deficits at 10 and 30 million cells/kg and a therapeutic time window up to 72 hr after stroke. © 2011 Wiley-Liss, Inc... - Combined neuroprotective modalities coupled with thrombolysis in acute ischemic stroke: a pilot study of caffeinol and mild hypothermiaSheryl Martin-Schild
Department of Neurology, University of Texas Houston Medical School, Houston, TX, USA
J Stroke Cerebrovasc Dis 18:86-96. 2009..We tested whether combining caffeinol and hypothermia with tissue plasminogen activator (t-PA) in patients with acute stroke is safe and feasible... - Is the drip-and-ship approach to delivering thrombolysis for acute ischemic stroke safe?Sheryl Martin-Schild
Department of Neurology, University of Texas Houston Health Science Center, Houston, Texas, USA
J Emerg Med 41:135-41. 2011..The drip-and-ship method of treating stroke patients may increase the use of tissue plasminogen activator (t-PA) in community hospitals... - Bone marrow mononuclear cells protect neurons and modulate microglia in cell culture models of ischemic strokeSushil Sharma
Department of Neurology, University of Texas Medical School at Houston, Houston, Texas 77030, USA
J Neurosci Res 88:2869-76. 2010..MNCs provide broad neuroprotection against a variety of injuries relevant to stroke... - IL-10 directly protects cortical neurons by activating PI-3 kinase and STAT-3 pathwaysSushil Sharma
Department of Neurology, Stroke Program, University of Texas Medical School at Houston, Houston, TX 77030, USA
Brain Res 1373:189-94. 2011..These data suggest that IL-10 provides neuroprotection by acting via IL-10 receptor and PI3K/AKT and STAT-3 signal transduction pathways... - Anticoagulation after cardioembolic stroke: to bridge or not to bridge?Hen Hallevi
Department of Neurology, University of Texas Health Science Center at Houston, 6431 Fannin St, MSB 7 044, Houston, TX 77030, USA
Arch Neurol 65:1169-73. 2008..Outcome measures and adverse events were collected prospectively. Laboratory values were captured from the records... - The complications of cardioembolic stroke: lessons from the VISTA databaseHen Hallevi
University of Texas at Houston, Vascular Neurology Program, Houston, Tex 77030, USA
Cerebrovasc Dis 26:38-40. 2008..Cardioembolic stroke (CES) accounts for 20-30% of ischemic strokes. We attempted to describe the complications of CES... - Pharmacological deep vein thrombosis prophylaxis does not lead to hematoma expansion in intracerebral hemorrhage with intraventricular extensionTzu Ching Wu
Department of Neurology, The University of Texas Houston Medical School, 6431 Fannin Street Suite, Houston, TX 77030, USA
Stroke 42:705-9. 2011..However, insufficient data exist on hematoma volume in patients with ICH before and after pharmacological deep venous thrombosis prophylaxis, leaving physicians with uncertainty regarding the safety of this practice... - Aggressive blood pressure-lowering treatment before intravenous tissue plasminogen activator therapy in acute ischemic strokeSheryl Martin-Schild
Vascular Neurology Program, Department of Neurology, University of Texas Health Science Center at Houston, 6431 Fannin St, Medical School Bldg Room 7 128, Houston, TX 77030, USA
Arch Neurol 65:1174-8. 2008..We evaluated the effect of elevated BP and its management on clinical outcomes after tPA therapy in AIS... - Safety of eptifibatide for subcortical stroke progressionSheryl Martin-Schild
Department of Neurology, University of Texas Houston Medical School, Houston, TX, USA
Cerebrovasc Dis 28:595-600. 2009..There is no proven treatment for stroke progression in patients with subcortical infarcts. Eptifibatide, a glycoprotein IIb/IIIa inhibitor, might halt stroke progression by improving flow in the microcirculation... - Future of neuroprotection for acute stroke: in the aftermath of the SAINT trialsSean I Savitz
Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
Ann Neurol 61:396-402. 2007..We discuss new suggestions to bridge the chasm between preclinical animal modeling and acute human stroke trials to potentially enhance the future assessment of novel neuroprotective drugs... - The IVH score: a novel tool for estimating intraventricular hemorrhage volume: clinical and research implicationsHen Hallevi
Department of Neurology, University of Texas Health Science Center at Houston, Houston, TX, USA
Crit Care Med 37:969-74, e1. 2009..Intraventricular extension of intracerebral hemorrhage (IVH) is an independent predictor of poor outcome. IVH volume may be important in outcome prediction and management; however, it is difficult to measure routinely... - Autologous bone marrow mononuclear cells enhance recovery after acute ischemic stroke in young and middle-aged ratsMiranda Brenneman
Department ofNeurology, University of Texas, Houston Medical School, Houston, Texas 77030, USA
J Cereb Blood Flow Metab 30:140-9. 2010..Autologous bone marrow MNCs can be safely harvested from rodents after stroke, migrate to the peri-infarct area, enhance recovery, and modulate the post-ischemic inflammatory response... - Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trialsMaria Philip
Department of Neurology, University of Texas Houston Medical School, Houston, TX 77030, USA
Stroke 40:577-81. 2009..We analyzed the quality and adequacy of animal studies supporting the efficacy of NXY-059 and other neuroprotective agents that are currently being investigated in phase II/III trials... - Intracerebral hemorrhage in cocaine usersSheryl Martin-Schild
Department of Neurology, Tulane University, New Orleans, LA, USA
Stroke 41:680-4. 2010..Cocaine is a cause of intracerebral hemorrhage (ICH), but there are no large studies that have characterized the location, pathology, and outcome of patients with cocaine-associated ICH... - Nitric oxide facilitates delivery and mediates improved outcome of autologous bone marrow mononuclear cells in a rodent stroke modelMallikarjunarao Kasam
Department of Neurology, Stroke Team, The University of Texas Houston Medical School, Houston, Texas, United States of America
PLoS ONE 7:e32793. 2012..The objective of this study was to determine the relevance of vasoactive mediators, generated in response to MNC injection, as factors regulating cerebral perfusion (CP), the biodistribution of MNC, and outcome in stroke... - Deleterious role of TNF-alpha in retinal ischemia-reperfusion injurySamuel Berger
Department of Neurology, SUNY Downstate Medical Center, Brooklyn, New York11203, USA
Invest Ophthalmol Vis Sci 49:3605-10. 2008..This study was conducted to further elucidate the role of TNF-alpha and its receptor in an in vivo model of retinal ischemia-reperfusion injury by investigating its effects on retinal histopathology and function... - Prophylactic neuroprotectionSean I Savitz
Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
Curr Drug Targets 8:846-9. 2007..This review will focus on which target populations should be considered for prophylactic neuroprotection trials and which drugs might be used in such trials... - Effect of needle diameter and flow rate on rat and human mesenchymal stromal cell characterization and viabilityPeter A Walker
Department of Pediatric Surgery, University of Texas Medical School at Houston, Houston, Texas 77030, USA
Tissue Eng Part C Methods 16:989-97. 2010..We hypothesize that injection of rat and human MSCs through various clinically relevant-sized catheters and flow rates will not affect cell viability, characterization, or function... - Cell therapy for strokeSean I Savitz
Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
NeuroRx 1:406-14. 2004..We emphasize the current, limited knowledge about the biology of implant sources and discuss special conditions in stroke that will impact the potential success of neurotransplantation in clinical trials... - Current practice versus willingness to enroll in clinical trials: paradox among vascular neurologists about treatment for acute ischemic strokeRamy El Khoury
Department of Neurology, University of Texas in Houston, Houston, Texas 77030, USA
Stroke 41:2038-43. 2010..Clinical trials are assessing the efficacy of fibrinolysis in extended time windows for acute ischemic stroke... - Bone marrow-derived mononuclear cell populations in pediatric and adult patientsMatthew T Harting
Department of Pediatric Surgery, University of Texas Medical School at Houston, Houston, Texas, USA
Cytotherapy 11:480-4. 2009..Concern has been raised that autologous MNC derived from elderly patients may be less effective as a therapeutic option... - A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of strokeSean I Savitz
Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Palmer 127, Boston, MA 02215, USA
Exp Neurol 205:20-5. 2007..Future neuroprotective agents need more rigorous testing in animal models of focal cerebral ischemia and appropriate evaluation in clinical studies that better match the preclinical data... - Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effectUwe M Fischer
Department of Pediatric Surgery, University of Texas Medical School at Houston, 6431 Fannin Street, Houston, TX 77030, USA
Stem Cells Dev 18:683-92. 2009..Larger stem and progenitor cells are initially trapped inside the lungs following intravenous administration with a therapeutically questionable number of cells reaching the arterial system acutely... - Diagnosis and initial management of cerebellar infarctionJonathan A Edlow
Department of Emergency Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA
Lancet Neurol 7:951-64. 2008..Here, we review the clinical presentation of cerebellar infarction, from diagnosis and misdiagnosis to patients' monitoring, treatment, and potential complications... - Neurotransplantation of fetal porcine cells in patients with basal ganglia infarcts: a preliminary safety and feasibility studySean I Savitz
Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass. 02215, USA
Cerebrovasc Dis 20:101-7. 2005..The study was terminated by the FDA after the inclusion of 5 patients. CONCLUSION: This is the first report on the transplantation of nontumor cells in ischemic stroke patients... - Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trialsJeffrey L Saver
Department of Neurology, Geffen School of Medicine, UCLA, Los Angeles, CA, USA
Stroke 40:2594-600. 2009..a. thrombolysis or devices may be acceptable. Statistical considerations and definitions of successful recanalization/reperfusion are suggested for these trials... - EDG receptors as a potential therapeutic target in retinal ischemia-reperfusion injurySean I Savitz
Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, USA
Brain Res 1118:168-75. 2006..These results suggest that LPA receptor signaling may play an important role in neuroprotection in retinal ischemia-reperfusion injury... - Update of the stroke therapy academic industry roundtable preclinical recommendationsMarc Fisher
Department of Neurology, University of Massachusetts Medical School, Worcester, MA 01605, USA
Stroke 40:2244-50. 2009..Although the recommendations cannot be validated until effective therapies based on them emerge from clinical trials, it is hoped that adherence to them might enhance the chances for success... - Arterial occlusive lesions recanalize more frequently in women than in men after intravenous tissue plasminogen activator administration for acute strokeSean I Savitz
Division of Cerebrovascular Disease, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Palmer 127, Boston, MA 02215, USA
Stroke 36:1447-51. 2005..CONCLUSIONS: In our cohort, vascular occlusive lesions were more likely to recanalize in women than men in response to IV tPA. These preliminary findings need to be validated in larger prospective studies... - Progenitor cell therapy for the treatment of central nervous system injury: a review of the state of current clinical trialsPeter A Walker
Department of Surgery, Medical School at Houston, University of Texas, 6431 Fannin Street, MSB 5 236, Houston, TX 77030, USA
Stem Cells Int 2010:369578. 2010.... - Vertebrobasilar diseaseSean I Savitz
Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
N Engl J Med 352:2618-26. 2005 - Pitfalls in the diagnosis of cerebellar infarctionSean I Savitz
Departments of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Acad Emerg Med 14:63-8. 2007..Cerebellar infarctions are an important cause of neurologic disease. Failure to recognize and rapidly diagnose cerebellar infarction may lead to serious morbidity and mortality due to hydrocephalus and brain stem infarction... - Intra-arterial delivery of cell therapies for strokeVivek Misra
1 Department of Neurology, University of Texas Medical School at Houston, UT Health, Houston, Texas
Stem Cells Dev 21:1007-15. 2012..This article reviews the trial methodology and procedural details of these studies and discusses the rationale and challenges in designing IA cell therapy trials for ischemic stroke... - The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety studyAndrew D Barreto
Department of Neurology, University of Texas Houston Medical School, Houston, TX, USA
Stroke 43:770-5. 2012..The Argatroban tPA Stroke Study was an open-label, pilot safety study of tPA plus Argatroban in patients with ischemic stroke due to proximal intracranial occlusion... - Investigational therapies for ischemic stroke: neuroprotection and neurorecoveryPreeti Sahota
Department of Neurology, University of Texas Medical School at Houston, Houston, TX 77030, USA
Neurotherapeutics 8:434-51. 2011..In this review, we highlight select pharmacologic and cell-based therapies that are currently in the clinical trial stage for stroke... - Vertebral artery compression of the medullaSean I Savitz
Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass 02215, USA
Arch Neurol 63:234-41. 2006..Much less is known about vertebral artery compression of the medulla... - Ischemic preconditioning is mediated by erythropoietin through PI-3 kinase signaling in an animal model of transient ischemic attackSamit Malhotra
Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA
J Neurosci Res 83:19-27. 2006..05). Pretreatment with the PI-3 kinase inhibitor wortmannin abolished the protective effect of IP against ischemic injury (P < 0.05). IP may be mediated in part by EPO through a PI-3 kinase pathway... - Linking Notch signaling to ischemic strokeJoseph F Arboleda-Velasquez
Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 105:4856-61. 2008.... - Cell transplantation for strokeSean I Savitz
Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
Ann Neurol 52:266-75. 2002..The survival, integration, and efficacy of neural transplants in stroke patients will depend on the type, severity, chronicity, adequacy of circulation, and location of the stroke lesion... - Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injuryAnna K Junk
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Proc Natl Acad Sci U S A 99:10659-64. 2002..These results further establish EPO as a neuroprotective agent in acute neuronal ischemic injury... - NXY-059 for the treatment of strokeSean I Savitz
N Engl J Med 357:2198; author reply 2198-9. 2007 - Neuroprotective effects of prostaglandin A(1) in rat models of permanent focal cerebral ischemia are associated with nuclear factor-kappaB inhibition and peroxisome proliferator-activated receptor-gamma up-regulationHui Ling Zhang
Department of Pharmacology and Laboratory of Aging and Nervous Diseases, Soochow University School of Medicine, Suzhou, China
J Neurosci Res 86:1132-41. 2008..These findings suggest that PGA(1)-mediated neuroprotective effect against ischemia appears to be associated with blocking NF-kappaB activation and likely with up-regulating PPAR-gamma expression... - Telemedicine is crucial to implementing acute stroke therapySean I Savitz
MedGenMed 8:39. 2006